Literature DB >> 16909480

Basal or bolus dose, which is the key factor in CSII?

Nai-long Yang1, Bing Xue, Peng Lin.   

Abstract

OBJECTIVE: To observe the value of HbA(1)c level evaluating the total daily basal insulin dose by continuous subcutaneous insulin infusion (CSII) in 268 patients with type 2 diabetes mellitus.
METHODS: 5-point capillary blood glucose was monitored in pre- and post-CSII and the insulin dose which could stabilize blood glucose was defined as the total daily dose of insulin, including basal and bolus total dose. Correlation between HbA(1)c level and total daily dose of insulin in patients with type 2 diabetes mellitus was analyzed. Correlation between HbA(1)c level and 5-point capillary blood glucose was also analyzed.
RESULTS: Obvious correlation was observed between HbA(1)c level and the basal total daily dose of insulin if HbA(1)c was more than 9.3% (r=0.635, P<0.05). The average of 5-point capillary blood glucose was best correlated with HbA(1)c and fasting blood glucose next best.
CONCLUSION: HbA(1)c level can forecast basal total daily dose of insulin in CSII.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16909480      PMCID: PMC1559801          DOI: 10.1631/jzus.2006.B0763

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  6 in total

1.  Relationship between fasting and day-long plasma glucose concentrations in diet-treated patients with type 2 diabetes.

Authors:  F Abbasi; Gerald M Reaven
Journal:  Metabolism       Date:  2002-04       Impact factor: 8.694

2.  Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes.

Authors:  B Zinman
Journal:  Endocr Pract       Date:  2000 Jan-Feb       Impact factor: 3.443

3.  Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control.

Authors:  E Bonora; F Calcaterra; S Lombardi; N Bonfante; G Formentini; R C Bonadonna; M Muggeo
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

4.  Efficacy of insulin pump therapy: mealtime delivery is the key factor.

Authors:  L M Crawford; R N Sinha; R M Odell; R J Comi
Journal:  Endocr Pract       Date:  2000 May-Jun       Impact factor: 3.443

5.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

Authors:  Louis Monnier; Hélène Lapinski; Claude Colette
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

6.  A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series.

Authors:  Treyce S Knee; Daniel F Seidensticker; Judy L Walton; Larissa M Solberg; David H Lasseter
Journal:  Endocr Pract       Date:  2003 May-Jun       Impact factor: 3.443

  6 in total
  1 in total

Review 1.  Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies.

Authors:  Guido Freckmann; Sina Buck; Delia Waldenmaier; Bernhard Kulzer; Oliver Schnell; Ulrich Gelchsheimer; Ralph Ziegler; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2020-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.